the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients

Recruiting Phase 4 Interventional Study
Ischemic Stroke Alteplase Adverse Reaction
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
716 (estimated)
Sponsor
Kafrelsheikh University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The investigators evaluated the impact of AF on different subtypes of post-alteplase hemorrhagic transformation of brain infarction.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * The investigators enrolled individuals of both genders, aged between 18 and 75, * All patients had acute first-ever embolic ischemic stroke and were eligible for thrombolysis. * All patients had Atrial fibrillation Exclusion Criteria: * The investigators excluded patients wh…
Contacts

mohamed G. Zeinhom, MD

2001009606828

mohamed_gomaa@med.kfs.edu.eg

CONTACT

sherihan R. ahmed, MD

2001113432342

sherihan_rezq@med.kfs.edu.eg

CONTACT